Table 4 |
|
|
Adverse events during the observation period |
|
|
Number (percentage) |
|
|
|
|
|
Asymptomatic bradycardia |
2 (5) |
|
Symptomatic bradycardia |
0 (0) |
|
Increase in norepinephrine dosage |
9 (22.5) |
|
Decrease in cardiac index |
7 (17.5) |
|
Decrease in cardiac index and ScvO2 |
1 (2.5) |
|
Decrease in stroke volume index |
2 (5) |
|
Increase in milrinone dosage |
6 (15) |
|
|
|
|
ScvO2, central venous oxygen saturation. |
|
|
Schmittinger et al. Critical Care 2008 12:R99 doi:10.1186/cc6976 |
|
